Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies

Publish date:: October 7, 2020

Key clinical point: Acalabrutinib showed better progression-free survival and overall survival than other frontline chronic lymphocytic leukemia therapies.

Major finding: Overall survival hazard ratios ranged from 0.18 to 0.65 in favor of acalabrutinib-based treatment, but not all were significant.

Study details: Efficacy of acalabrutinib in ELEVATE-TN was compared with data from eight other randomized, controlled trials.

Disclosures: AstraZeneca sponsored the study. The authors reported funding from AstraZeneca and numerous other pharmaceutical companies.

Citation:

Davids MS et al. Clin Ther. 2020 Oct 5. doi: 10.1016/j.clinthera.2020.08.017.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CLL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Ibrutinib associated with decreased circulating malignant cells and restored T-cell function in CLL patients,

Final ASCEND study data: Acalabrutinib beat standard of care for r/r CLL,

Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapies,